Domnick Martin, Domnick Manju, Wiebelitz Karl-Rüdiger, Beer André-Michael
Praxisklinik und internistische Gemeinschaftspraxis Domnick, Herten, Germany.
Oncology. 2017;93(2):83-91. doi: 10.1159/000468939. Epub 2017 May 5.
Evidence for complementary therapies as important strategies to relieve cancer treatment-associated symptoms is increasing. Mostly, these complementary therapies start at the end of adjuvant treatments, resulting in a long delay until the well-being of patients is addressed. Further, long distances between the rehabilitation center and the patients' residence hinder patients' compliance.
The multimodal outpatient LOTUS Care Cure Project (LCCP) was tested in a randomized controlled trial including patients of various cancer entities and stages while on adjuvant chemotherapy and/or radiotherapy or outpatient aftercare. The intervention group received the LCCP additionally to the conventional treatment (LCCP group, n = 50). The control group (CG) was split into 2 groups, with (CG1, n = 33) and without (CG2, n = 17) weekly talks. The primary endpoint was quality of life (QoL) after 3 months.
In the LCCP group, QoL significantly improved after 3 months compared to CG2 (p = 0.022) but not compared to CG1. Other parameters showing a significant improvement were cognitive (p < 0.05, vs. CG1 and CG2) and social function (p < 0.05, vs. CG2).
This pilot study describes a multimodal outpatient complementary therapy program conducted in parallel with conventional therapies and its potential to significantly improve QoL and reduce treatment-associated side effects. To substantiate these data, multicenter trials are needed.
作为缓解癌症治疗相关症状的重要策略,补充疗法的证据越来越多。大多数情况下,这些补充疗法在辅助治疗结束时才开始,导致在解决患者的健康问题之前有很长的延迟。此外,康复中心与患者住所之间的距离较远,阻碍了患者的依从性。
在一项随机对照试验中对多模式门诊LOTUS护理治疗项目(LCCP)进行了测试,该试验纳入了处于辅助化疗和/或放疗阶段或门诊随访阶段的各种癌症类型和分期的患者。干预组在接受常规治疗的基础上额外接受LCCP(LCCP组,n = 50)。对照组(CG)分为两组,一组(CG1,n = 33)有每周谈话,另一组(CG2,n = 17)没有每周谈话。主要终点是3个月后的生活质量(QoL)。
与CG2相比,LCCP组在3个月后QoL有显著改善(p = 0.022),但与CG1相比无显著差异。其他显示有显著改善的参数是认知(与CG1和CG2相比,p < 0.05)和社会功能(与CG2相比,p < 0.05)。
这项初步研究描述了一项与传统疗法并行开展的多模式门诊补充治疗项目及其显著改善QoL和减少治疗相关副作用的潜力。为证实这些数据,需要进行多中心试验。